ArticleEndocrine, metabolic & immune disorders drug targets2026
Expression of IL-35 in the Prophase of Liver Failure and its Immune Regulatory Interaction with Glucocorticoids.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo investigate the immunoregulatory role of interleukin-35 (IL-35) in the prophase of liver failure related to hepatitis B virus (HBV-PLF) and its synergistic mechanism with glucocorticoid treatment.
methods22 patients with HBV-PLF (matched with 22 healthy controls) were included. Peripheral blood regulatory T cells (Treg)/helper T cells 17 (Th17) ratio, serum IL-35/IL-17 dynamic changes, and liver function indicators were measured both before and after methylprednisolone treatment (1 mg/kg, 7 days). A concanavalin A-induced PLF mouse model was used to evaluate the effects of IL-35 overexpression, IL-35 neutralizing antibody, and dexamethasone on liver injury, cytokines, and the hepatic immune microenvironment.
resultsCompared with healthy controls, patients with HBV-PLF exhibited a significantly reduced Treg/Th17 ratio and elevated serum IL-35 levels at baseline (p < 0.05). Following methylprednisolone treatment, both serum IL-35 levels and the Treg/Th17 ratio increased, with IL-35 levels showing a strong positive correlation with the Treg/Th17 ratio (r = 0.69). In the mouse model, IL-35 overexpression significantly alleviated liver injury, showing a hepatoprotective effect comparable to that of dexamethasone (p > 0.05). This improvement was characterized by decreased alanine aminotransferase levels and improved histopathological scores (p < 0.05). In contrast, administration of an IL-35 neutralizing antibody was found to exacerbate damage. Mechanistic investigations revealed that IL-35 promoted the proportion of hepatic FOXP3+ Treg cells while inhibiting Th17 activation, thereby establishing the Treg/Th17 balance. DISCUSSION: This study demonstrates the dynamic immunoregulatory role of IL-35 in PLF through clinical observations and mechanistic validation in a mouse model. IL-35 was closely associated with restoration of the Treg/Th17 balance and showed hepatoprotective effects comparable to glucocorticoids, suggesting its potential as a target for early immunomodulatory intervention.
conclusionIL-35 serves as a critical regulator of immune homeostasis in PLF. Glucocorticoids appear to exert their protective effects by upregulating IL-35 expression. Consequently, targeting the IL-35 pathway represents a promising strategy for early intervention in liver failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.